Abstract | BACKGROUND: Disseminated coccidioidomycosis (which is caused by the endemic fungi of the genus Coccidioides) can be a life-threatening systemic fungal infection. Although conventional antifungal therapies have activity against Coccidioides, the disease can be refractory to standard therapies. Drug-associated toxicities also may limit the clinical utility of the standard antifungal drugs. In addition, relapses in patients with disseminated coccidioidomycosis are common, making long-term management of this disease challenging. METHODS: RESULTS: At the end of therapy, 5 of 6 patients had successful outcomes. Posaconazole was well tolerated despite long-term administration (1-2 years), and 2 patients continued to receive posaconazole maintenance therapy at the time of writing. CONCLUSIONS:
|
Authors | Gregory M Anstead, Gavin Corcoran, James Lewis, Deborah Berg, John R Graybill |
Journal | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
(Clin Infect Dis)
Vol. 40
Issue 12
Pg. 1770-6
(Jun 15 2005)
ISSN: 1537-6591 [Electronic] United States |
PMID | 15909265
(Publication Type: Case Reports, Journal Article, Research Support, U.S. Gov't, Non-P.H.S.)
|
Chemical References |
- Antifungal Agents
- Triazoles
- posaconazole
|
Topics |
- Adolescent
- Adult
- Antifungal Agents
(therapeutic use)
- Coccidioidomycosis
(drug therapy, pathology)
- Dermatomycoses
(drug therapy, pathology)
- Drug Administration Schedule
- Female
- Humans
- Male
- Middle Aged
- Skin
(pathology)
- Triazoles
(therapeutic use)
|